Visual Atlas · Science

The neuroplasticity of psilocybin

One molecule, measurable structural change. Psilocybin reshapes neural architecture in hours, not weeks — here is the mechanism, the evidence tier, and the caveat that matters for microdosing.

90-second quick read · deeper research available

Need the deeper research library?

This is the 90-second cliff-note read on imicrodosing.net. For cited research context, terminology, and broader education, use the full .org research library.

Read the full neuroplasticity research →Browse related 90-second reads →

24 hrsSpine growth window

2018Ly et al., Cell Reports

5-HT2ATrigger receptor

In brief

Cell and animal studies link psychedelic exposure with plasticity-related signaling and structural change. Those findings do not establish the same timing, magnitude, or benefit in human microdosing.

Human studies support acute brain and network effects, while direct structural confirmation and microdose-specific outcome evidence remain limited.

Visual walkthrough

Cover: the brain is not fixed. How one molecule reshapes neural architecture, and what the evidence shows.

What neuroplasticity is: the brain's capacity to form, strengthen, and reorganise neural connections throughout life.

The physical substrate of plasticity: dendritic spines, the protrusions where neurons form synaptic connections.

Meet BDNF, brain-derived neurotrophic factor — a protein supporting the survival and growth of neurons.

What BDNF does: promotes synapse formation and dendritic growth; low levels are associated with depression.

Slide illustrating proposed 5-HT2A-linked plasticity pathways; direct structural evidence is strongest in preclinical studies.

Slide describing preclinical dendritic-spine findings from Ly et al. 2018.

Slide showing a proposed preclinical time course; human microdosing timing is not established.

Network effect: increased plasticity coincides with altered activity in the default mode network.

Critical periods: heightened-plasticity windows that psychedelics may transiently reopen in the adult brain.

The caveat: most direct structural evidence is preclinical — cortical cultures and rodents, not human microdosers.

Slide discussing the hypothesis that context influences how plasticity-related changes are expressed.

Closing slide noting that plasticity findings do not by themselves determine a beneficial outcome.

1 / 13

Swipe or tap the arrows to move through 13 slides

From receptor binding to structural change

Receptor first

Psilocin engages 5-HT2A receptors, which participate in acute psychedelic effects. Plasticity-related pathways are studied across cell, animal, and human models, and no single step explains every outcome.

BDNF and growth pathways

Preclinical studies link psychedelic exposure with plasticity-related signaling, including TrkB and mTOR pathways. Translation to human microdosing remains uncertain.

Dendritic spines

Ly et al. 2018 reported structural plasticity effects in cell and animal models. Those findings do not establish the same magnitude or timing in human microdosing.

Speed

Some preclinical changes occurred within hours to days. Comparisons with antidepressant onset are not direct evidence of superior or faster human benefit.

Persistence

Some preclinical structural changes persisted after acute drug clearance. Human durability and clinical meaning remain under study.

The evidence tier

The direct structural data is preclinical. Human structural confirmation is earlier-stage, and microdose-specific structural data earlier still.

What the data shows — and how strong it is

Strong Clinical + mechanisticModerate Survey + trackingEarly Promising, developingAnecdotal Widely reported only

Strong

Strong — preclinical structural plasticityLy et al. 2018 (Cell Reports, DOI 10.1016/j.celrep.2018.05.022) showed increased dendritic spine density and synaptogenesis in vitro and in vivo across psychedelic classes, dependent on TrkB, mTOR and 5-HT2A signalling. Robust and replicated in rodents.

Moderate

Moderate — mechanism in humansImaging and biomarker work supports increased plasticity-related signalling in humans after full doses. The receptor mechanism is well-characterised; downstream structural confirmation in humans is less direct than in rodents.

Early

Early — microdose translationWhether sub-perceptual doses produce the same structural changes as full doses is not established. Microdose-specific structural studies are sparse.

Verdict

Preclinical evidence supports plasticity-related effects. What those findings mean for human microdosing and durable outcomes remains unsettled.

Common questions

Answered directly

Q · 01

What is BDNF and what does psilocybin do to it?

BDNF (brain-derived neurotrophic factor) is a protein that supports neuron survival and synapse formation; low levels are associated with depression. Psilocybin, via 5-HT2A activation, drives BDNF signalling through the TrkB and mTOR pathways, which underlies the increase in dendritic spine density measured after dosing.

Q · 02

How fast does psilocybin change brain structure?

Ly et al. 2018 reported rapid structural changes in cell and animal models. That timing should not be transferred directly to human microdosing or compared as proof of faster clinical benefit.

Q · 03

Does microdosing produce the same neuroplasticity as a full dose?

This is not established. The strong structural evidence comes from full doses in cell cultures and rodents. Whether sub-perceptual doses drive the same magnitude of structural change in humans is an open question — the mechanism is compelling, the microdose-specific data early-stage.

Product-format context

For product-format context, see the iMicrodosing.com products and client support.

View products & support →

← AtlasAll 17 topics Next →Default mode network